-
2024-512195-35-00
5
Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-p
-
2024-517133-40-00
5
newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
-
2024-517295-37-00
5
low and intermediate risk neuroblastoma
-
2025-522335-34-00
3
Chronic kidney disease
-
2025-523586-18-00
5
Non-Small Cell Lung Cancer
-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2022-502825-17-00
4
2024-10-07
Melanoma
-
2026-525752-29-00
2
2026-06-01
bioavailability trial with healthy participants, therapeutic indicatio
-
2025-522091-84-00
4
2026-05-29
Merkel Cell Carcinoma
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2024-516544-26-00
4
2026-03-30
acute ischemic stroke
-
2025-521670-34-00
5
2026-03-04
Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or
-
2024-512503-39-00
6
2025-12-19
Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
-
2024-517136-21-00
5
2025-12-05
Renal Cell Carcinoma
-
2023-508612-29-00
5
2025-11-07
Advanced Melanoma
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-520264-33-00
5
2025-10-07
Locoregionally recurrent head and neck squamous cell carcinoma (HNSCC)
-
2024-519152-82-00
5
2025-09-03
Relapsed/Refractory Follicular Lymphoma
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2024-515561-34-01
6
2025-08-04
Acute ischemic stroke with recent ingestion of direct oral anticoagula
-
2024-516197-30-00
3
2025-07-16
Idiopathic or diabetic gastroparesis
-
2024-517647-31-00
4
2025-07-09
basal cell carcinoma